Search Product
Structure Search
Search
Online Support
-
Customer service
Advantage Products
Location: Industrial Info
Flufenamic acid has been verified to be effective against bladder cancer
2016-10-10
来源：转载自第三方
10 October 2016
Recently, researchers at Hokkaido University in Japan said they found that the commonly used non-steroidal anti-inflammatory analgesic "flufenamic acid" has the effect of inhibiting bladder cancer cell metastasis and reducing patient resistance. Related scientific research results has been published in the scientific journal "Scientific Reports" on October 4 [1].
Bladder cancer is a malignant tumor in the bladder mucosa, ranked ninth in the incidence of malignant tumors, and very easy to relapse. The clinical can be divided into two categories, non-muscular invasive bladder cancer (tumor confined to the mucosa and submucosa) and myometrial invasive bladder cancer (tumor invasion of the muscle and bladder structure). five years of survival rate of non-myometrial invasive bladder cancer is 90%, while that of myometrial invasive bladder cancer is less than 6%, cancer cells are easily transferred to the lungs and liver and other organs. In the clinical treatment, doctors generally use Cisplatin and other anti-cancer drugs to treat invasive cancer, but the patient's own drug resistance and cancer cell metastasis are the main causes of adverse prognosis. How to relieve the patient's resistance and inhibit the metastasis of cancer cells are the key issue in the prognosis of treatment.
In the paper, researchers said they found a metabolic enzyme, aldehyde-ketone reductase 1C1 (AKR1C1), have played a crucial role in cancer metastasis and drug resistance. In animal experiments, labeled bladder cancer cells migrate to the liver, lungs and bones after a period of time, and there is a high gene expression molecule in the metastatic cancer cells. Through the mRNA microarray technology survey, researchers found that in the transfer of cancer cells, the content of AKR1C1 increased by 3~25 times. The same phenomenon was observed in the pathology of human patients.
In the treatment of anticancer preparations, cancer cells die and at the same time, inflammation will occur around and release interleukin-1β, which will lead to the increase of aldehyde-ketone reductase in cancer cells, and then the patients will produce drug resistance, aldehyde-ketone reductase can also control the activity of cancer cells. (2{[3-(trifluoromethyl)benzene]amino}-benzoic acid, o-chlorobenzoic acid and m-trifluoromethyl aniline as the substrate, produced by the Ullman condensation reaction), can inhibit aldehyde-ketone reductase, and thus control the invasion and metastasis of cancer cells.
Flufenamic acid is a very inexpensive non-steroidal antiinflammatory analgesic agent, scientists found that it has an unexpected effect in the treatment of bladder cancer, if it is put into the bladder cancer cells, so that the activities of cancer cells stop, the anti-cancer agent can play a role again, to obtain a good therapeutic effect. Scientists have said they will continue to develop and expand their applications, if success, which will make a significant contribution to the treatment of cancer.
References
[1] Ryuji Matsumoto, Masumi Tsuda, Kazuhiko Yoshida, et al. Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells. Scientific Reports, 2016, doi: 10.1038/srep34625.
Related Links: Flufenamic Acid
Edited by Suzhou Yacoo Science Co., Ltd.
如果涉及转载授权，请联系我们。
